Wedbush Reaffirms “Outperform” Rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Wedbush reaffirmed their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) in a research note published on Tuesday morning, RTT News reports. They currently have a $30.00 price objective on the stock. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at $0.01 EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.02 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.24 EPS, FY2026 earnings at $0.80 EPS and FY2027 earnings at $1.26 EPS.

Separately, TheStreet upgraded Kiniksa Pharmaceuticals from a d+ rating to a c rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Trading Up 1.5 %

KNSA stock opened at $17.88 on Tuesday. The stock’s fifty day simple moving average is $19.27 and its two-hundred day simple moving average is $18.00. Kiniksa Pharmaceuticals has a 1-year low of $10.65 and a 1-year high of $22.09. The stock has a market cap of $1.26 billion, a P/E ratio of 162.55 and a beta of 0.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 23rd. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.11). Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. The business had revenue of $79.90 million during the quarter, compared to analysts’ expectations of $76.97 million. During the same period in the prior year, the firm posted ($0.18) EPS. The firm’s revenue for the quarter was up 65.4% on a year-over-year basis. As a group, analysts forecast that Kiniksa Pharmaceuticals will post 0.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $21.45, for a total value of $207,185.55. Following the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at $377,262.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CAO Michael R. Megna sold 5,126 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the sale, the chief accounting officer now directly owns 17,588 shares in the company, valued at approximately $383,242.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Michael R. Megna sold 9,659 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a total value of $207,185.55. Following the sale, the chief accounting officer now owns 17,588 shares in the company, valued at $377,262.60. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock worth $709,929 over the last ninety days. 54.23% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. IFP Advisors Inc bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $65,000. China Universal Asset Management Co. Ltd. increased its stake in Kiniksa Pharmaceuticals by 349.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,097 shares of the company’s stock worth $72,000 after acquiring an additional 3,186 shares during the last quarter. Victory Capital Management Inc. bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth about $176,000. Dynamic Technology Lab Private Ltd bought a new position in Kiniksa Pharmaceuticals in the 4th quarter worth about $213,000. Finally, QRG Capital Management Inc. bought a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth about $249,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.